Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
Background. One of the major challenges affecting sarcoma treatment outcome, particularly that of metastatic disease, is resistance to chemotherapy. Cancer-initiating cells are considered a major contributor to this resistance. Methods. An immortalised nontransformed human stromal (mesenchymal) stem...
Saved in:
Main Authors: | Ninna Aggerholm-Pedersen, Christina Demuth, Akmal Safwat, Peter Meldgaard, Moustapha Kassem, Boe Sandahl Sorensen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.1155/2016/9601493 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Haemorrhagic Colitis Caused by Dasatinib
by: Nishant Patodi, et al.
Published: (2012-01-01) -
Treatment of Cancer Gene Changes in Chronic Myeloid Leukemia by Big Data Analysis Platform-Based Dasatinib
by: Linlin Song, et al.
Published: (2022-01-01) -
Possible Protective Effect of Diacerein on Doxorubicin-Induced Nephrotoxicity in Rats
by: Marwa M. M. Refaie, et al.
Published: (2016-01-01) -
A Case of Retroperitoneal Synovial Sarcoma in Pregnancy Treated with Antepartum Doxorubicin plus Ifosfamide Chemotherapy
by: Bradley H. Sipe, et al.
Published: (2021-01-01) -
Dasatinib and FLAG-IDA Is an Effective Therapy for Initial Myeloid Blast Crisis but Involves a High Risk of Opportunistic Infections
by: Jorge Labrador, et al.
Published: (2020-01-01)